TKPHF - Takeda ProThera Collaboration And Other News: The Good Bad And Ugly Of Biopharma
Takeda Teams Up with ProThera on IAIP Therapy
Takeda Pharmaceutical Company Limited (TAK) announced inking a new deal with ProThera Biologics for the purpose of developing IAIP therapy. This plasma-derived therapy is intended to be used for treating acute inflammatory conditions. Both the companies will work together for carrying out the preliminary work leading to the start of clinical trials. Takeda is expected to lead the efforts towards the filing of IND.
The global licensing deals with IAIP which is a naturally occurring protein circulating in the blood. The research conducted by ProThera